Entrada Therapeutics

Founded 2016 · Biotech · Public

Intracellular delivery platform for therapeutic biologics using proprietary cell-penetrating peptide technology

Claim this profile

Follows are private to you and power your alerts

Updated · entradatx.com

Sector
Biotech
Founded
2016
Latest Form D
$116M, Apr 2021
Total capital
$151M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$151M
3 Form D · last Apr 2021
66 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
8
32 pending · first 2020
Rank in peer group#196 of 1449

Capital timeline

201620172018201920202021FEDERAL ↑EQUITY ↓Cumulative $151M1st Form D$600K2nd Form D$34M3rd Form D$116M
201620172018201920202021FEDERAL ↑EQUITY ↓Cumulative $151M2nd Form D$34M3rd Form D$116M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$116M
  • Private capital raisedForm D · SEC · 2nd filing$34M
  • Private capital raisedForm D · SEC · 1st filing$600K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#196 · top 14%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Anja HarmeierDirectorNamed in SEC Form D filings
  • Carole NuechterleinDirectorNamed in SEC Form D filings
  • Christine BrennanDirectorNamed in SEC Form D filings
  • Dehua PeiDirectorNamed in SEC Form D filings
  • Dipal DoshiExecutive Officer, DirectorNamed in SEC Form D filings
  • John F. CrowleyDirectorNamed in SEC Form D filings
Show all 17 people
  • John F. CrowleyDirectorNamed in SEC Form D filings
  • Kory WentworthExecutive OfficerNamed in SEC Form D filings
  • Kush M. ParmarDirectorNamed in SEC Form D filings
  • Kush M. ParmarDirectorNamed in SEC Form D filings
  • Louis TartagliaDirectorNamed in SEC Form D filings
  • Mario SaltarelliExecutive OfficerNamed in SEC Form D filings
  • Natarajan SethuramanExecutive OfficerNamed in SEC Form D filings
  • Nathan DowdenExecutive OfficerNamed in SEC Form D filings
  • Nerissa KreherExecutive OfficerNamed in SEC Form D filings
  • Peter KimDirectorNamed in SEC Form D filings
  • Todd FoleyDirectorNamed in SEC Form D filings

What it has protected

USPTO · 8 granted of 40
Show all 40 patent records
  • Compositions For Delivery Of Antisense CompoundsSep 22, 2026 · US 12,741,989Granted
  • Compositions And Methods For Treating Mitochondrial Neurogastrointestinal EncephalopathyAug 4, 2026 · US 12,698,482Granted
  • Cyclic Cell Penetrating PeptidesJul 16, 2026 · Application 19630088Pending
  • Compositions And Methods For Delivery Of Nucleic Acid TherapeuticsJun 18, 2026 · Application 18862670Pending
  • Hybrid OligonucleotidesJan 29, 2026 · Application 18993485Pending
  • Cyclic Peptides For Delivering TherapeuticsSep 18, 2025 · Application 18858718Pending
  • Synthesis Of Fmoc-protected Morpholino Monomers And OligomersAug 5, 2025 · US 12,378,267Granted
  • Cyclic Cell Penetrating PeptidesJul 31, 2025 · Application 18553379Pending
  • Intracellular Targeting Of OligonucleotidesJul 17, 2025 · Application 18698647Pending
  • Compounds And Methods For Skipping Exon 44 In Duchenne Muscular DystrophyApr 24, 2025 · Application 18688083Pending
  • Compositions And Methods For Treating Mitochondrial Neurogastrointestinal EncephalopathyApr 10, 2025 · Application 18620636Pending
  • Compositions And Methods For Modulating Interferon Regulatory FACTOR-5 (IRF-5) ActivityFeb 13, 2025 · Application 18289943Pending
  • COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICINGFeb 13, 2025 · Application 18289946Pending
  • Cell Penetrating Peptides And Methods Of Making And Using ThereofJan 9, 2025 · Application 18734759Pending
  • Antisense Compounds And Methods For Targeting Cug RepeatsJan 9, 2025 · Application 18390717Pending
  • Compositions And Methods For Skipping Exon 45 In Duchenne Muscular DystrophyDec 19, 2024 · Application 18688096Pending
  • Compositions And Methods For Intracellular TherapeuticsOct 31, 2024 · Application 18560080Pending
  • Compositions And Methods For Modulating Gene ExpressionJul 25, 2024 · Application 18289944Pending
  • Cyclic Cell Penetrating PeptidesJul 25, 2024 · Application 18506057Pending
  • Compositions And Methods For Treating Mitochondrial Neurogastrointestinal EncephalopathyMay 21, 2024 · US 11,987,821Granted
  • Methods For The Sequencing Of Phosphorodiamidate Morpholino Oligomers (pmo) And Peptide-pmo (ppmo) ConjugatesMar 14, 2024 · Application 18238725Pending
  • Cyclic Cell Penetrating PeptidesOct 5, 2023 · Application 18128669Pending
  • Antigen-binding And Antigen Degradation ConstructsJan 26, 2023 · Application 17739943Pending
  • Cell Penetrating Peptides And Methods Of Making And Using ThereofJun 9, 2022 · Application 17530664Pending
  • Cell Penetrating Peptides And Methods Of Making And Using ThereofJan 18, 2022 · US 11,225,506Granted
  • Compositions And Methods For Treating Mitochondrial Neurogastrointestinal EncephalopathyNov 9, 2021 · US 11,168,310Granted
  • Cell Penetrating Peptides And Methods Of Making And Using ThereofOct 27, 2020 · US 10,815,276Granted
  • Cell Penetrating Peptides And Methods Of Making And Using ThereofApr 21, 2020 · US 10,626,147Granted
  • Compounds And Methods For Skipping Exon 51 In Duchenne Muscular DystrophyApplication 63743956Pending
  • Compounds And Methods For Skipping Exon 50 In Duchenne Muscular DystrophyApplication PCTUS2024048282Pending
  • Ocular Delivery Of Therapeutic AgentsApplication 19115637Pending
  • Compounds And Methods For Skipping Exon 51 In Duchenne Muscular DystrophyApplication 63803259Pending
  • Compounds And Method For Treating Myotonic Dystrophy Type 1Application 63758796Pending
  • Compounds And Methods For Skipping Exon 51 In Duchenne Muscular DystrophyApplication PCTUS2026010732Pending
  • Cyclic Peptides For Delivering TherapeuticsApplication 63561539Pending
  • Intracellular Targeting Of OligonucleotidesApplication 63737028Pending
  • Compounds And Method For Treating Myotonic Dystrophy Type 1Application 63779922Pending
  • Intracellular Targeting Of OligonucleotidesApplication 63859568Pending
  • Compounds And Methods For Skipping Exon 50 In Duchenne Muscular DystrophyApplication 63640506Pending
  • Intracellular Targeting Of OligonucleotidesApplication 63640478Pending
  • Immorta Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • AraviveSimilar federal contract value in Biotech · null in contracts
  • SonoTheraSimilar federal contract value in Biotech · null in contracts
  • Pelage PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
  • Hexagon Bio Inc.Similar federal contract value in Biotech · null in contracts
  • Dovetail Genomics, LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .